List of Excipients in API macitentan and tadalafil
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing macitentan and tadalafil
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Actelion Pharmaceuticals US Inc | OPSYNVI | macitentan and tadalafil | 66215-814 | CELLULOSE, MICROCRYSTALLINE | 2031-03-22 |
| Actelion Pharmaceuticals US Inc | OPSYNVI | macitentan and tadalafil | 66215-814 | HYDROXYPROPYL CELLULOSE | 2031-03-22 |
| Actelion Pharmaceuticals US Inc | OPSYNVI | macitentan and tadalafil | 66215-814 | HYPROMELLOSE | 2031-03-22 |
| Actelion Pharmaceuticals US Inc | OPSYNVI | macitentan and tadalafil | 66215-814 | LACTOSE MONOHYDRATE | 2031-03-22 |
| Actelion Pharmaceuticals US Inc | OPSYNVI | macitentan and tadalafil | 66215-814 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | 2031-03-22 |
| Actelion Pharmaceuticals US Inc | OPSYNVI | macitentan and tadalafil | 66215-814 | MAGNESIUM STEARATE | 2031-03-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for macitentan and tadalafil
Excipient focus: CELLULOSE, MICROCRYSTALLINE
macitentan and tadalafil drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
macitentan and tadalafil drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
macitentan and tadalafil drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
macitentan and tadalafil drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
macitentan and tadalafil drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
macitentan and tadalafil drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
macitentan and tadalafil drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
macitentan and tadalafil drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
macitentan and tadalafil drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A
macitentan and tadalafil drug variants containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
macitentan and tadalafil drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
macitentan and tadalafil drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
macitentan and tadalafil drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Actelion Pharmaceuticals US Inc | macitentan and tadalafil | 66215-814 |
| >Company | >Ingredient | >NDC |
macitentan and tadalafil drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch